David A. Weinstein, M.D., M.M.Sc.
Glycogen Storage Disease
While patients with glycogen storage disease are now surviving into adulthood, long-term complications remain common, and Dr. Weinstein's team has focused on elucidating the cause of these complications. Previous studies have revealed the pathophysiology for anemia and renal complications in GSD, and Dr. Weinstein's lab continues to investigate complications in GSD I including hepatocellular carcinoma, hepatic adenomas, and athersclerosis. Curing the glycogen storage diseases remains the ultimate goal. Dr. Weinstein's laboratory is working on ways to cure the disease through gene therapy or replacement of glucose-6-phosphatase activity. Stem cell therapy is presently being attempted in the mice with GSD type Ia, and gene therapy is being performed in the naturally occurring canine model of this disease.
Not Accepting New Students This Year
Following his graduation from Trinity College (CT) and Harvard Medical School, Dr. Weinstein completed a residency, chief residency, and fellowship in pediatric endocrinology at Children's Hospital Boston. He subsequently obtained a Masters in clinical investigation from Harvard and MIT, and became Director of the Glycogen Storage Disease Program at Children's Hospital Boston. In 2005, Dr. Weinstein moved to the University of Florida where he directs the Glycogen Storage Disease Program and is an Associate Professor of Pediatrics. Dr. Weinstein follows the largest cohort of hepatic GSD patients in the world, and he has published 20 articles and 15 textbook chapters on this topic. He is a former Jan Albrecht Award winner from the American Association for the Study of Liver Diseases, and he is on the Board of Directors for the Association for Glycogen Storage Disease.
BMB Home Research Areas BMB Faculty